Literature DB >> 30936124

One Clever Macrophage Checkpoint.

Alberto Mantovani1,2,3, Raffaella Bonecchi4,2.   

Abstract

Macrophages are a key component of the tumor microenvironment (TME). Blocking Clever-1, a molecule expressed in M2-like macrophages, unleashed macrophage and T-cell-mediated antitumor immunity. Myeloid checkpoints including Clever-1 hold promise as alternative or complementary immunotherapy strategies.See related article by Viitala et al., p. 3289. ©2019 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30936124      PMCID： PMC7174017          DOI： 10.1158/1078-0432.CCR-19-0483

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


  5 in total

1.  Immunotherapeutic Blockade of Macrophage Clever-1 Reactivates the CD8+ T-cell Response against Immunosuppressive Tumors.

Authors:  Miro Viitala; Reetta Virtakoivu; Sina Tadayon; Jenna Rannikko; Sirpa Jalkanen; Maija Hollmén
Journal:  Clin Cancer Res       Date:  2019-02-12       Impact factor: 12.531

2.  The macrophage tetraspan MS4A4A enhances dectin-1-dependent NK cell-mediated resistance to metastasis.

Authors:  Irene Mattiola; Federica Tomay; Maria De Pizzol; Rita Silva-Gomes; Benedetta Savino; Tamara Gulic; Andrea Doni; Silvia Lonardi; Marie Astrid Boutet; Alessandra Nerviani; Roberta Carriero; Martina Molgora; Matteo Stravalaci; Diego Morone; Irina N Shalova; Yunquin Lee; Subhra K Biswas; Giovanna Mantovani; Marina Sironi; Costantino Pitzalis; William Vermi; Barbara Bottazzi; Alberto Mantovani; Massimo Locati
Journal:  Nat Immunol       Date:  2019-07-01       Impact factor: 25.606

3.  Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial.

Authors:  Paul M Ridker; Jean G MacFadyen; Tom Thuren; Brendan M Everett; Peter Libby; Robert J Glynn
Journal:  Lancet       Date:  2017-08-27       Impact factor: 79.321

4.  CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma.

Authors:  Ranjana Advani; Ian Flinn; Leslie Popplewell; Andres Forero; Nancy L Bartlett; Nilanjan Ghosh; Justin Kline; Mark Roschewski; Ann LaCasce; Graham P Collins; Thu Tran; Judith Lynn; James Y Chen; Jens-Peter Volkmer; Balaji Agoram; Jie Huang; Ravindra Majeti; Irving L Weissman; Chris H Takimoto; Mark P Chao; Sonali M Smith
Journal:  N Engl J Med       Date:  2018-11-01       Impact factor: 91.245

Review 5.  Tumour-associated macrophages as treatment targets in oncology.

Authors:  Alberto Mantovani; Federica Marchesi; Alberto Malesci; Luigi Laghi; Paola Allavena
Journal:  Nat Rev Clin Oncol       Date:  2017-01-24       Impact factor: 66.675
  5 in total
  2 in total

Review 1.  Diversity, Mechanisms, and Significance of Macrophage Plasticity.

Authors:  Massimo Locati; Graziella Curtale; Alberto Mantovani
Journal:  Annu Rev Pathol       Date:  2019-09-17       Impact factor: 23.472

Review 2.  Exploiting Manipulated Small Extracellular Vesicles to Subvert Immunosuppression at the Tumor Microenvironment through Mannose Receptor/CD206 Targeting.

Authors:  Maria Luisa Fiani; Valeria Barreca; Massimo Sargiacomo; Flavia Ferrantelli; Francesco Manfredi; Maurizio Federico
Journal:  Int J Mol Sci       Date:  2020-08-31       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.